STRATA Skin Sciences Inc (SSKN)
Official siteMEDICAL DEVICES
Last updated: Nov 13, 2026 at 4:00 PM ET
STRATA Skin Sciences Inc (SSKN) Financials: Revenue, Profit and Cash Flow
STRATA Skin Sciences reported revenue of $30.70M for the fiscal year ended Dec 31, 2025, down 8.5% from the year before. That year, net income was -$6.26M with a net margin of -20.4%, operating cash flow was -$2.79M and free cash flow was -$4.26M. The quarter ended Dec 31, 2025 had revenue of $9.29M and net income of $282.00K.
Revenue and Margins
The operating margin was -15.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue was little changed from $30.71M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $30.70M | -8.5% | 58.3% | -15.3% | -20.4% |
| Dec 2024 | $33.56M | +0.6% | 57.3% | -27.6% | -30.1% |
| Dec 2023 | $33.36M | -7.8% | 55.3% | -25.8% | -32.5% |
| Dec 2022 | $36.16M | +20.6% | 60.2% | -12.9% | -15.3% |
| Dec 2021 | $29.98M | +29.8% | 66.2% | -14.7% | -9.0% |
| Dec 2020 | $23.09M | -26.9% | 61.2% | -17.7% | -19.1% |
| Dec 2019 | $31.59M | +5.8% | 64.2% | -9.5% | -12.0% |
| Dec 2018 | $29.86M | -6.0% | 57.3% | -11.2% | -13.5% |
| Dec 2017 | $31.76M | +3.4% | 59.1% | -5.7% | -67.7% |
| Dec 2016 | $30.71M | N/A | 58.8% | -11.7% | -10.9% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.70M | $33.56M | $33.36M | $36.16M | $29.98M | $23.09M | $31.59M | $29.86M | $31.76M | $30.71M |
| Cost of revenue | $12.81M | $14.34M | $14.90M | $14.39M | $10.13M | $8.96M | $11.32M | $12.73M | $13.00M | $12.64M |
| Gross profit | $17.88M | $19.22M | $18.46M | $21.77M | $19.85M | $14.13M | $20.27M | $17.12M | $18.77M | $18.07M |
| Research and development | $421.00K | $883.00K | $1.32M | $1.03M | $1.43M | $1.27M | $1.00M | $1.06M | $1.71M | $1.93M |
| Operating income | -$4.70M | -$9.26M | -$8.60M | -$4.65M | -$4.40M | -$4.08M | -$3.01M | -$3.35M | -$1.80M | -$3.60M |
| Net income | -$6.26M | -$10.09M | -$10.83M | -$5.55M | -$2.71M | -$4.41M | -$3.79M | -$4.03M | -$21.51M | -$3.33M |
| EBITDA | -$76.00K | -$2.94M | -$2.56M | $1.20M | $1.71M | -$165.00K | $1.99M | $2.24M | $9.44M | $10.86M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.29M | $6.93M | $7.66M | $6.81M | $9.58M | $8.80M | $8.44M | $6.75M | $8.69M | $8.85M | $8.25M | $7.57M |
| Gross profit | $5.74M | $4.18M | $4.31M | $3.65M | $5.88M | $5.29M | $4.98M | $3.08M | $4.80M | $4.95M | $4.32M | $4.39M |
| Operating income | $712.00K | -$1.17M | -$2.22M | -$2.02M | -$4.28M | -$1.60M | -$486.00K | -$2.89M | -$3.44M | -$615.00K | -$1.96M | -$2.59M |
| Net income | $282.00K | -$1.62M | -$2.49M | -$2.43M | -$4.54M | -$2.07M | -$99.00K | -$3.37M | -$3.79M | -$1.05M | -$3.15M | -$2.83M |
Balance Sheet
As of Dec 2025, total debt of $15.35M exceeded cash and equivalents by $7.44M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $30.52M | $34.93M | $42.02M | $52.27M | $46.59M | $46.78M | $47.34M | $47.51M | $39.13M | $43.19M |
| Current assets | $15.60M | $16.59M | $15.54M | $15.05M | $19.97M | $24.83M | $23.55M | $23.21M | $10.75M | $3.93M |
| Cash and equivalents | $7.91M | $7.26M | $6.78M | $5.43M | $12.59M | $10.60M | $8.13M | $16.49M | $4.07M | $3.93M |
| Total liabilities | $27.61M | $29.96M | $29.33M | $30.44M | $21.18M | $20.89M | $18.69M | $16.26M | $19.25M | $28.16M |
| Short-term debt | $15.35M | $0 | $352.00K | $355.00K | $318.00K | $8.75M | $7.28M | $252.00K | $2.39M | $2.05M |
| Long-term debt | $0 | $15.19M | $15.04M | $7.48M | $7.32M | $1.05M | $0 | $7.14M | $7.85M | $21.78M |
| Shareholder equity | $2.91M | $4.97M | $12.69M | $21.83M | $25.41M | $25.89M | $28.65M | $31.25M | $19.88M | $15.04M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $30.52M | $30.72M | $30.72M | $34.26M | $36.16M | $40.20M | $39.58M | $40.05M | $42.02M | $47.19M | $55.20M | $49.12M |
| Total liabilities | $27.61M | $29.40M | $30.41M | $31.59M | $31.18M | $30.86M | $30.09M | $30.62M | $29.33M | $31.00M | $38.30M | $29.80M |
| Cash and equivalents | $7.91M | $7.08M | $5.97M | $6.51M | $7.26M | $7.06M | $5.48M | $5.24M | $6.78M | $7.13M | $9.03M | $2.83M |
| Shareholder equity | $2.91M | $1.31M | $308.00K | $2.67M | $4.97M | $9.34M | $9.50M | $9.43M | $12.69M | $16.19M | $16.91M | $19.32M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.79M | $188.00K | -$519.00K | -$924.00K | $1.51M | $2.10M | $2.23M | $2.90M | $4.14M | $322.00K |
| Capital expenditures | $1.47M | $1.64M | $5.02M | $3.74M | $3.65M | $2.16M | $115.00K | $13.00K | $320.00K | $0 |
| Free cash flow | -$4.26M | -$1.45M | -$5.54M | -$4.66M | -$2.15M | -$63.00K | $2.11M | $2.88M | $3.82M | $322.00K |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.34M | $0 | N/A |
| Investing cash flow | -$1.47M | -$1.64M | -$5.02M | -$4.37M | -$7.13M | -$2.16M | -$2.79M | -$1.78M | -$2.19M | -$868.00K |
| Financing cash flow | $3.58M | $1.93M | $6.86M | -$500.00K | $92.00K | $2.55M | -$296.00K | $11.31M | -$1.80M | $1.17M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$239.00K | -$64.00K | -$1.94M | -$550.00K | $703.00K | -$302.00K | $591.00K | -$804.00K | $1.37M | -$2.02M | $947.00K | -$817.00K |
| Capital expenditures | $312.00K | $1.02M | $61.00K | $199.00K | $504.00K | $62.00K | $345.00K | $725.00K | $1.72M | $194.00K | $1.70M | $1.79M |
| Free cash flow | -$551.00K | -$1.08M | -$2.00M | -$749.00K | $199.00K | -$364.00K | $246.00K | -$1.53M | -$347.00K | -$2.21M | -$756.00K | -$2.61M |
Frequently Asked Questions About SSKN
What is STRATA Skin Sciences' annual revenue?
STRATA Skin Sciences reported revenue of $30.70M for the fiscal year ended Dec 31, 2025.
How fast is STRATA Skin Sciences' revenue growing?
Revenue was down 8.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.3%.
Is STRATA Skin Sciences profitable?
No. STRATA Skin Sciences reported net income of -$6.26M for the fiscal year ended Dec 31, 2025, with a net margin of -20.4%.
How much free cash flow does SSKN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$2.79M minus capital expenditures of $1.47M produced free cash flow of -$4.26M.
How much debt does STRATA Skin Sciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $15.35M and cash and equivalents of $7.91M.
SSKN pages: Overview, Financials